Partnering

Pipeline Expansion

Selective product in-licensing or acquisition will enable Context Therapeutics to rapidly build a diversified pipeline of T cell engaging bispecific antibodies to treat solid tumors.

SOURCE. Academia, startup, or pharma.

STAGE. Preclinical development through Phase 2-ready.

TYPE. T cell engaging (TCE) bispecific antibody for solid tumors.

Our Science

Developing T cell engaging (TCE) bispecific antibody therapies to treat solid tumors.

Go

Our Pipeline

Context’s pipeline includes TCEs targeting Claudin 6 (CLDN6), mesothelin (MSLN), and Nectin-4.

Go

Email Alerts

Be the first to receive breaking news.

Sign Up